Urol. praxi. 2017;18(4):165-168 | DOI: 10.36290/uro.2017.038

Serenoa repens in the treatment of benign prostatic hyperplasia

MUDr. Jiří Slíva, Ph.D.
Ústav farmakologie 3. LF UK, Praha

Benign prostatic hyperplasia is a very prevalent disease requiring long-term effective and safe treatment. The importance ofphytotherapy has been discussed for years and is also mentioned in the recent therapeutic guidelines. The article describes thecurrent position of these products with a dominant focus on Serenoa repens.

Keywords: BPH, benign prostatic hyperplasia, prostatic gland, Serenoa, treatment, LUTS

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Serenoa repens in the treatment of benign prostatic hyperplasia. Urol. praxi. 2017;18(4):165-168. doi: 10.36290/uro.2017.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. La VC, Levi F, Lucchini F. Mortality from benign prostatic hyperplasia: worldwide trends 1950-1992. J. Epidemiol. Community Health 1995; 49: 379-384. Go to original source...
    2. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. 1993; 150: 85-89. Go to original source... Go to PubMed...
    3. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17: 241-246. Go to original source... Go to PubMed...
    4. Vela NR, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez FA. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003; 44: 549-555. Go to original source... Go to PubMed...
    5. Bernichtein S, Pigat N, Camparo P, et al. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon(R)) in a mouse model of prostate hyperplasia. Prostate 2015; 75: 706-722. Go to original source... Go to PubMed...
    6. Latil A, Petrissans MT, Rouquet J, Robert G, de la Taille A. Effects of hexanic extract of Serenoa repens (Permixon(R) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 2015; 75: 1857-1867. Go to original source... Go to PubMed...
    7. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate 2000; 45: 259-266. Go to original source...
    8. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 2000; 164: 876-881. Go to original source... Go to PubMed...
    9. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999; 40: 232-241. Go to original source...
    10. Habib FK. The Scientific Basis for the Treatment of Benign Prostatic Hyperplasia. Eur Urol Suppl. 2009; 8: 887-893. Go to original source...
    11. Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 2015; 67: 1099-1109. Go to original source... Go to PubMed...
    12. Wilt TJ, Ishani A, Rutks I, Macdonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 2000; 3: 459-472. Go to original source... Go to PubMed...
    13. Wilt TJ, Ishani A, Stark G, Macdonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-1609. Go to original source... Go to PubMed...
    14. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane. Database. Syst. Rev 2012; 12: CD001423. Go to original source... Go to PubMed...
    15. Scaglione F. How to Choose the Right Serenoa repens Extract. Eur Urol. Suppl. 2015; 14: e1464-e1469. Go to original source...
    16. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 2005; 48: 269-276. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.